Associate Professor Matthew Greenhawt
Associate Professor of Pediatrics, University of Colorado
School of Medicine (Aurora, CO, US), Department of Pediatrics,
Section of Allergy/Immunology, Children's Hospital Colorado
Dr Greenhawt earned his medical degree from Tufts University School of Medicine, Boston, Massachusetts; completed a pediatrics residency at Morgan Stanley Children’s Hospital of New York-Presbyterian, Columbia Presbyterian Medical Center, New York, New York, and an allergy/immunology fellowship at the University of Michigan in Ann Arbor, Michigan. He also holds an MBA from Tufts University and a master’s of science degree in health and healthcare policy from the University of Michigan, Rackham School of Graduate Studies. Dr Greenhawt is an Associate Professor with the Department of Pediatrics, Section of Allergy and Immunology at Children’s Hospital Colorado and the University of Colorado School of Medicine, and is the director for the Children’s Hospital Colorado Food Challenge and Research Unit.
Dr Greenhawt is board certified in Pediatrics and Allergy/Immunology. He is a member of the American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, and European Academy of Allergy and Clinical Immunology. He is an associate editor for the Annals of Allergy, Asthma and Immunology, and a member of the Joint Taskforce of Allergy Practice Parameters. Dr Greenhawt’s research interests include, shared decision making, food allergy cost-effectiveness and comparative effectiveness research, food-allergic diseases health services research, primary/secondary prevention and treatment of food allergy, and food allergy public policy. He has authored a number of peer-reviewed articles, abstracts, and book chapters. He is the immediate past chair of the ACAAI Food Allergy Committee, and is a member of multiple AAAAI, ACAAI, and EAACI committees.
Author's key paper
Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction.
Greenhawt M, Shaker M. JAMA Netw Open. 2019 Dec 2;2(12):e1918041. doi: 10.1001/jamanetworkopen.2019.18041. PMID: 31860109; PMCID: PMC6991237.
Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.
Shaker M, Greenhawt M. JAMA Netw Open. 2019 May 3;2(5):e193242. doi: 10.1001/jamanetworkopen.2019.3242. PMID: 31050778; PMCID: PMC6503512.
Professor Julie Bines, MBBS, FRACP, MD, AGAF
Department of Paediatrics, Melbourne Medical School,
University of Melbourne
Murdoch Children's Research Institute, Royal Children's Hospital
Julie is the Victor and Loti Smorgon Professor of Paediatrics at the University of Melbourne and Head of Clinical Nutrition at the Royal Children’s Hospital. She leads the Enteric Disease Group at Murdoch Children’s Research Institute working to develop an affordable novel rotavirus vaccine, RV3-BB vaccine, aimed at preventing rotavirus disease from birth in infants worldwide. She has led clinical trial of this vaccine in Australia, New Zealand, Indonesia and Malawi. Professor Bines is Director of the WHO Collaborative Centre for Child Health and the WHO Rotavirus Regional Reference Laboratory for the Western Pacific Region. She has served as a consultant for WHO in a number of roles including on the Steering Committee for Enteric Disease Vaccines and the development of the roadmap for assessment of Vaccines against Antimicrobial resistance and developed the generic protocol for vaccine safety surveillance for rotavirus vaccines and the Brighton Collaboration clinical case definition for intussusception.
Author's key paper
Human Neonatal Rotavirus Vaccine (RV3-BB) to target rotavirus from birth.
Bines JE, AT Thobari J, Satris CD, Handley A, Watts E, Cowley D, Newati HN, Ackland J, Standish J, Justice F, Icanervilla AJ, Byars G, Lee KJ, Bachtair NS, Barnes GL, Bishop RF, Kirkwood CD, Buttery JC, Soenarto YD.
New England Journal of Medicine 2018: 378:719-30.
PD Dr med Erich Rutz, MD, PhD Candidate
The University of Basel, Switzerland & Danube University Krems, Austria
Murdoch Children's Research Institute, MCRI
Orthopaedic Department, Royal Children's Hospital
Hugh Williamson Gait Laboratory
Dr Erich Rutz has recently joined the orthopaedic department and The Hugh Williamson Gait Laboratory at the Royal Children’s Hospital (RCH). For the last 15 years he worked as a consultant at the University Children’s Hospital Basel, Switzerland, where he was Head of the Gait Laboratory and Head of Neuromuscular Hip Surgery Programme.
He has a strong interest in all neuromuscular conditions and in particular in cerebral palsy (CP). 10 years ago he worked as a research fellow in the Hugh Williamson Gait Laboratory at RCH on a major project “Outcomes of Single-event Multilevel Surgery (SEMLS)” in children with CP. Erich focuses on the surgical treatment of disabled, ambulant and non-ambulant, children. His surgical expertise is in both surgery for ambulant children (SEMLS) and one-stage, hip reconstruction. Dr Rutz has experience in and enjoys the challenges of all areas of paediatric orthopaedics and trauma surgery.
He has written more than 60 scientific papers and 17 book chapters and completed his habilitation thesis (“Venia Docendi”) in 2013 at the medical faculty of the University Basel, which is the highest university degree that can be awarded for orthopaedics and traumatology of the musculoskeletal system. In addition the completion of his PhD thesis in biomechanics is intended by end of 2020. Dr. Rutz’ academic work has been recognised by eight national and international awards.
In his leisure time he enjoys spending time with his family, playing the violoncello, and (pre COVID-19) travelling for teaching and holiday.
Author's key paper
Stability of the Gross Motor Function Classification System after single-event multilevel surgery in children with cerebral palsy
Erich Rutz 1, Oren Tirosh, Pam Thomason, Alexej Barg, H Kerr Graham.
Dev Med Child Neurol 2012 Dec;54(12):1109-13.